Clinical Trial

Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction

Study acronym: HEARTPOWER
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
A randomized controlled trial was conducted to evaluate the efficacy and safety of Yangxinshi tablets in improving the condition of patients with coronary heart disease complicated by cardiac dysfunction.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-30.
Status change: Not Yet Recruiting → Recruiting 2025-11-20
Trial Details
NCT Number NCT07110415
Lead Sponsor SPH Qingdao Growful Pharmacetical Co.,Ltd
Conditions Coronary Heart Disease, Cardiac Dysfunction
Enrollment 2,708 participants
Start Date 2025-11-06
Primary Completion 2030-08-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-25